C Gennigens
Overview
Explore the profile of C Gennigens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Powell M, Bjorge L, Willmott L, Novak Z, Black D, Gilbert L, et al.
Ann Oncol
. 2024 Jun;
35(8):728-738.
PMID: 38866180
Background: Part 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin-paclitaxel compared with placebo plus carboplatin-paclitaxel in patients with primary advanced or recurrent endometrial cancer (EC). At the first...
2.
Vergote I, Van Nieuwenhuysen E, Casado A, Laenen A, Lorusso D, Braicu E, et al.
Gynecol Oncol
. 2023 May;
174:80-88.
PMID: 37167896
Objective: Nintedanib is an oral tyrosine kinase inhibitor targeting, among others, vascular endothelial growth factor receptor. The aim was to establish the role of nintedanib in addition to paclitaxel and...
3.
Gennigens C, Jerusalem G, Lapaille L, De Cuypere M, Streel S, Kridelka F, et al.
ESMO Open
. 2022 Sep;
7(5):100579.
PMID: 36108558
Despite screening programs for early detection and the approval of human papillomavirus vaccines, around 6% of women with cervical cancer (CC) are discovered with primary metastatic disease. Moreover, one-third of...
4.
Lamarca A, Morfouace M, Tejpar S, Oliveira J, Capela A, Penel N, et al.
Ann Oncol
. 2022 Aug;
33(11):1200-1202.
PMID: 35926814
No abstract available.
5.
Vergote I, Denys H, Altintas S, Kerger J, Baurain J, Bours V, et al.
Facts Views Vis Obgyn
. 2022 Jul;
14(2):111-120.
PMID: 35781107
Ovarian cancer (OC) has a poor prognosis as most patients present with non-specific symptoms and the disease is mostly diagnosed at advanced stages. Approximately 90% of cases are classified as...
6.
Mettlen C, Gennigens C, Kurth W
Rev Med Liege
. 2022 Jan;
77(1):5-7.
PMID: 35029333
The use of mega-joint prostheses has become common practice in the field of reconstructive orthopedic surgery. These new implants are considered as the gold standard for reconstruction after joint and...
7.
Lapaille L, De Cuypere M, Goffin F, Kakkos A, Gonne E, Hermesse J, et al.
Rev Med Liege
. 2021 Jun;
76(5-6):507-514.
PMID: 34080388
Cervical cancer is the fourth most common cancer in women and is linked in over 95 % of cases to papillomavirus infection, the incidence of which has fallen in recent...
8.
Vergote I, Denys H, De Greve J, Gennigens C, Van de Vijver K, Kerger J, et al.
Facts Views Vis Obgyn
. 2020 Oct;
12(3):227-239.
PMID: 33123697
Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking...
9.
Gonne E, Collignon J, Jerusalem G, Gennigens C
Rev Med Liege
. 2017 Apr;
71(10):449-454.
PMID: 28383853
Carcinomas of unknown primary (CUP) form a whole group of heterogeneous neoplasias. CUP are defined as metastatic epithelial tumors in which the initial work up has failed to detect the...
10.
Collignon J, Gennigens C, Jerusalem G
PET Clin
. 2016 May;
5(3):311-26.
PMID: 27157836
Bone is one of the most common sites of metastases from cancer. Most anticancer treatments are highly toxic but only a fraction of all patients respond to them. Guidelines are...